Evidence map›Paper›PMID 40373279›Full record

ArticleBlood2025

Defective neutrophil clearance in JAK2V617F myeloproliferative neoplasms drives myelofibrosis via immune checkpoint CD24.

Eman Khatib-Massalha, Christian A Di Buduo, Agathe L Chédeville, Ya-Hsuan Ho, Yexuan Zhu, Elodie Grockowiak, Yuki Date, Lam T Khuat, Zijian Fang, José Quesada-Salas and 6 more

Abstract read
In one paragraph

Article in Blood, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Eman Khatib-MassalhaCambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.
Christian A Di BuduoDepartment of Molecular Medicine, University of Pavia, Pavia, Italy.ORCID 0000-0002-6472-2008
Agathe L ChédevilleInstituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain.ORCID 0009-0001-8002-1738
Ya-Hsuan HoCambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.
Yexuan ZhuCambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.
Elodie GrockowiakCambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.
Yuki DateCambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.
Lam T KhuatCambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.
Zijian FangCambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.
José Quesada-SalasInstituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain.ORCID 0009-0004-3119-6664
Eva Carrillo FélezCambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.
Matteo MigliavaccaDepartment of Molecular Medicine, University of Pavia, Pavia, Italy.
Isabel MonteroDepartment of Hematology, University Hospital Virgen del Rocío, Seville, Spain.
José A Pérez-SimónInstituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain.
Alessandra BalduiniDepartment of Molecular Medicine, University of Pavia, Pavia, Italy.ORCID 0000-0003-3145-1245
Simón Méndez-FerrerCambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-9805-9988

Funding

Wellcome Trust 203151Wellcome Trust 226795
6 · The paper itself

Abstract

abstractMyeloproliferative neoplasms (MPNs) are hematopoietic stem cell-driven malignancies marked by excessive myelopoiesis and high risk of myelofibrosis, which remains therapeutically challenging. Senescent neutrophils home daily to the bone marrow (BM) to be cleared by macrophages. This avoids their accumulation, which can increase the risk of chronic inflammation or oncogenesis. Neutrophils carrying the most common oncogenic MPN driver (JAK2V617F) are protected from apoptosis, which may prolong their life span and enhance their proinflammatory activity. In contrast, abnormal interactions of neutrophils with megakaryocytes ("emperipolesis") have been associated with BM fibrosis in disparate hematologic disorders, including MPN and gray platelet syndrome; however, the underlying pathophysiology remains unclear. We investigated neutrophil homeostasis and cellular interactions in MPN. We found that senescent neutrophils evade homeostatic clearance and accumulate in JAK2V617F MPN, but not in MPN caused by the second most prevalent mutations affecting calreticulin gene. This is explained by granulocyte-macrophage colony-stimulating factor-JAK2-STAT5-dependent upregulation of the "don't eat me" signal CD24 in neutrophils. Mechanistically, JAK2V617F CD24hi neutrophils evade efferocytosis, invade megakaryocytes, and increase active transforming growth factor β (TGF-β). Collectively, JAK2V617F neutrophil-megakaryocyte interactions promote platelet production in a humanized bioreactor and myelofibrosis in mouse models. Notably, chronic antibody blockade or genetic loss of CD24 restores clearance of senescent neutrophils and reduces emperipolesis and active TGF-β. Consequently, CD24 blockade improves thrombocytosis and prevents myelofibrosis in MPN mice. Taken together, these findings reveal defective neutrophil clearance as a cause of pathogenic microenvironmental interactions of inflammatory neutrophils with megakaryocytes, associated with myelofibrosis in MPN. Our study postulates CD24 as a candidate innate immune checkpoint in MPN.

Indexed as

CD24 AntigenJanus Kinase 2Mutation, MissenseMyeloproliferative DisordersNeutrophilsPrimary MyelofibrosisAnimalsHumansMegakaryocytesMiceCD24 AntigenJAK2 protein, humanJanus Kinase 2

Identifiers

PMID40373279
PMCPMC7618514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.